Life Sciences Archive » February, 2018

Life Sciences - February, 2018

266 articles

• Del. Class Suit Over Weight Loss Drug Trial Leaks Tossed
• King & Spalding DQ'd In Boehringer Unit Arbitration
• Deals Rumor Mill: Bayer, Embraer, NIO
• Mallinckrodt Hit With Subpoena To Provide Opioid Info
• Nelson Mullins Opens Baltimore Office With 11 New Hires
• MedImmune Spins Drugs Into New Biotech Co., Raises $250M
• Cherokee Slam Bid To Take Opioid Suit To Federal Court
• Drug Cos. Want Blue Cross Unit Sanctioned In Aggrenox MDL
• Shkreli Argues For Short Prison Stint Ahead Of Sentencing
• Doc Admits Letting Aegerion See Patient Data, Target Teens
• King & Spalding Nabs Cooley's Ex-IP Litigation Head
• Ex-Merck Exec Settles With SEC Over Insider Trading Claims
• Zimmer Must Face Majority Of NJ Hip Implant Suit
• DOJ Unveils Opioid Task Force, Eyes Foray Into Ohio MDL
• Ex-Drug Distribution Exec Convicted In $50M Scheme
• Natus Medical Slips Investor Suit Over Venezuela Contract
• FTC Says Robocalls Misled Consumers As Cos. Return Fire
• CVS, Aetna Pitch Lawmakers On Merger Benefits
• Calif. Can't Require Monsanto To Add Weed Killer Warning
• Full Fed. Circ. Urged To Rethink Illumina Patent Challenge
• FDA Warning Wire: False Data, Cleanliness Issues Overseas
• Vitamin C Importers Urge Justices To Revive Antitrust Suit
• Why Machine Learning Should Matter To Lawyers
• Ky. Can't Reclaim Firm's $4.2M Cut Of OxyContin Settlement
• Navigating The Complexities Of A Digital Health Transaction
• Litigating The Internet Of Things
• Claim Scope And Apportionment At Fed. Circ.
• Jury Sides With Pfizer, Serono In Biogen's IP Spat
• In Surprising Move, PTAB Tackles Tribal Immunity Head-On
• Plaintiffs Agree To Release Pfizer From Testosterone MDL
• Judge Keeps Retaliation Suit Against Medical Co. Alive
• Allergan Urges 1st Circ. To Reverse Asacol Class Cert.
• GSK Hid Zofran Data From FDA, Families Say
• Shkreli Caused $10.4M In Losses, Not Zero, Judge Rules
• Judge Orders Redo In First AbbVie Testosterone MDL Trial
• Doctor Charged Over Sharing Patient Info With Aegerion
• Tribe Not Immune From Restasis IP Challenges, PTAB Says
• Health Hires: Goodwin, Alston & Bird, Lucas & Mercanti
• Meningitis Pharmacist Must Forfeit $175K Before Restitution
• Amgen Denied Full Fed. Circ. Hearing On Repatha Patents
• Amgen Fears 'Staggering Loss' After FDA Exclusivity Denial
• Judge Won't Disturb Jury Verdict On Health Supplement IP
• Fed. Circ. 'Divided' On Patent Eligibility, Justices Told
• No 'Rubber Stamp' For SEC Penalties In NJ Biotech Fraud Row
• Endo, Auxilium And GSK Reach Deal In Testosterone MDL
• Opioid MDL Attys Clash With DEA Over Drug Data
• Shkreli Can't Beat Stock Fraud Rap Post-Trial
• Valeant Says Stomach Ulcer Drug Is Being Imported Unfairly
• US Steps Into Tricare FCA Suit Against Pharmacy, PE Owner
• Man Will Die From J&J Talc-Caused Mesothelioma, Jury Told
• 4th Circ. Resurrects Medical Device Co. Investor Suit
• Endo Settles Rest Of Lidoderm Antitrust Suit
• Rituxan Patent Survives Celltrion, Pfizer PTAB Challenges
• 2 Biotechs Brave Volatility To Raise $401M In Follow-Ons
• 6th Circ. Won't Revive Spinal Patients' Bone Growth Suit
• Horizon Pharma Fired Aegerion's FCA Whistleblower: Suit
• 2 Tibet Pharma Defendants May Appeal Last Count In IPO Suit
• GSK Has Duty To Warn About Generics, Widow Tells 7th Circ.
• Dorsey Scores Team Of 10 IP Attys From Holland & Hart
• Calif. Justices Take Up Actavis' Opioid Suit Coverage Bid
• Insurance Tips For Defendants In Opioid Litigation
• The Continuing Evolution Of Personal Jurisdiction
• Ex-Herbalife Sellers Blast Arbitration Bid In $1B RICO Suit
• AIG Denied Quick Win In Becton Antitrust Coverage Fight
• DC Circuit Urged To Knock Down FDA E-Cig Rule
• CooperVision To Pay $3M To End Contact Price-Fixing Suit
• Express Scripts Beats NY Pharmacy's Antitrust, Contract Suit
• Xarelto User Says Pa. Judge Wrongly Axed $28M Award
• Surgical Robotics Co. Reaps $118M In Private Financing
• Feds Can't Get Israeli Court Info In $163M Perrigo Tax Row
• From NJ To Texas: How The Courts Fared At The Fed. Circ.
• Purdue Pharma Triggered Opioid Epidemic, NJ County Says
• Pa. Justices Urged To Deny Appeal Over Risperdal Time-Bar
• A New Weapon To Help FDA Control Enforcement Priorities
• California's Evolving Standard On Expert Opinion Evidence
• Biotech Co. Says Rival Violated Deal With Press Releases
• Patient Says AbbVie's New Trial Needs To Be On All Claims
• Amgen Seeks To Hold Off Generics In FDA Denial Challenge
• Expert Tells NJ Jury He Found Asbestos In J&J Talc
• 4 Cos. Restock IPO Pipeline With Filings Totaling $300M
• Has Rule 36 Peaked At The Federal Circuit?
• 'The Federal Circuit Has Strayed': 2017 In Patent Dissents
• King & Spalding DQ Bid Shouldn't Be Complex, Judge Says
• Pa. Court Won't Junk Risperdal Verdict Against J&J Unit
• FDA Warning Wire: Problems At Pfizer Plant
• High Court Won't Hear Lipitor, Effexor Pay-For-Delay Appeals
• Ex-Katten Muchin Atty Says Jury Misconduct Tainted Trial
• Justices Decline 'Vexatious' Patient's Suit Over CT Scan
• Ky. Says Distributor Failed To Police Opioid Prescriptions
• Emerging Patent Issues In The Cannabis Industry
• Meet The Attys At The Opioid MDL's Negotiating Table
• The Firms That Dominated At The Federal Circuit In 2017
• How The Federal Circuit's Patent Docket Changed In 2017
• Boston Scientific IP Attys Must Defend Doc-Redact Request
• Merck Unit Loses $2.5B Verdict As Hep C Patent Invalidated
• Allergan, Others Cough Up $9M In Product-Hopping Suit
• Insmed Beats Stock-Drop Suit Over Lung Disease Drug
• PTAB Will Review Amgen Patent Tied To Sanofi Eczema Drug
• Pharma Co. Chiasma Can't Escape Investor Suit, Judge Rules
• Momenta, Sandoz Can't Nix Drug Antitrust Suit, Court Told
• Lion Biotech Gets Some Claims Trimmed In Investor Dispute
• Pot Biz Urges Supreme Court To Take Case Against IRS
• Womble Bond Snags 3 Pepper Hamilton Gov't Contracts Attys
• 9th Circ. Won't Revive Investor Suit Over Hep B Drug Trials
• Taxation With Representation: Kirkland, Davis, Skadden, Weil
• Register Your California Cannabis Trademarks Now
• How Emerging Sources Of ESI Will Impact Discovery
• W.Va. Opioid Suit Against McKesson Sent Back To State Court
• Russian Arbitral Award OK'd Against No-Show Pharma Biz
• Bayer Claims Perrigo Infringed Finacea Drug Patents
• ABA Presses For Trade Secrets Safeguards In New NAFTA
• Shunt Patent Reissue Doomed By Recapture Rule: Fed. Circ.
• Bioverativ Shareholders Sue To Block $11.6B Sale To Sanofi
• Put The Brakes On Acceleration Bay Litigation Funder Ruling
• How Natural Experiments Can Help In Estimating Damages
• A Chat With Hogan Lovells HR Chief Allison Friend
• NuVasive Says Rival Hired Key Workers, Copied Spine System
• NY Pharma Sales Rep Cops To $45M Health Fraud Scheme
• Cascadian Investor Says $614M Deal Statement Omitted Info
• Deals Rumor Mill: Healthineers, Blackstone, Takata
• 11th Circ. Affirms 11-Year Stint For $80M Eli Lilly Drug Theft
• Pfizer Says Insurers Owe $30M For Off-Label Marketing Suit
• Ex-NFLer's Pot Decriminalization Suit Hits Possible Snag
• Pfizer Fights In 2nd Circ. Over Interest Claims Deadline
• Illumina Uses Mosaic Of Trial Assets To Score $27M IP Win
• Zimmer Reaches Tentative Settlement In Knee-Implant MDL
• Czech Republic Faces $1B In New Claims From Plasma Co.
• Medical Device, Biotech Cos. Price IPOs Raising $30M Total
• Nektar Inks $1.85B Bristol-Myers Cancer Drug Collaboration
• Considerations For Attorneys Using Artificial Intelligence
• 11th Circ. Asked To Rehear Amgen, Pfizer Win In Enbrel Suit
• Life Science Investor Suits Spiked In '17, Dechert Reports
• PTAB Won't Review 2 Humira Patents In Sandoz Challenge
• Clinical R&D Lab To Scoop Up Pharma Testing Co. For $800M
• 1st Circ. Denies Bid To Stall Solodyn Pay-For-Delay Trial
• Split 9th Circ. Backs EpiCept Win In Patent-Deal Suit
• Teva Exits Philly Reglan Mass Tort With Settlement
• FDA Warning Wire: Bayer's Botched Batches
• Deals Rumor Mill: Walgreens, Actera, Sberbank
• Bristol-Myers Hit With Sanctions Bid Over Abilify Notebooks
• $69M IPO Filed By Biotech That Uses AI To Develop Drugs
• What Hospitals Need To Know Before Forming A Drug Co.
• Agency Accused Of Running MLB Doping, Bribery Scheme
• Medical Device Co. Motus Downsizes IPO Estimate To $21M
• Meningitis Pharmacist Tells Court Restitution Is Too Much
• Eli Lilly Says Cymbalta Users Can't Reopen Axed Case
• Protecting Trade Secrets Disclosed To The FDA
• Will Big Drugmakers Mimic Purdue On Opioid Marketing?
• Expert Ignored Evidence J&J Talc Lacked Asbestos, Jury Told
• Sucampo Investor Seeks Docs For Proposed Mallinckrodt Deal
• Investors In Genocea Herpes-Drug Row Get Lead Counsel
• Vitamin Shoppe Dodges False Ad Suit Over Supplement
• Allergan To Pay $13.5M To End Doctors' Botox Pricing Suit
• Insurer Fights $17.3M In Coverage For Pelvic Mesh Claims
• Pa. Judge Oks J&J Unit's Pelvic Mesh Jurisdiction Appeal
• Bristol-Myers Oversold Lung Cancer Drug, Investors Say
• Shkreli Seeks Light Sentence, Saying His Victims Profited
• Adviser Who Traded On Tip From Atty Gets 6 Months In Prison
• Judging A Book: Duncan Reviews 'Justice And Empathy'
• Health-Focused PE Firm 1315 Capital Closes $300M Fund
• Emerging Trends In FCA Enforcement: 2018 Outlook
• 'Throw' Your Mini-Opening To Get The Best Jury Possible
• ITC Says UK DNA Sequencer Doesn't Violate PacBio Patent
• AbbVie Investor Demands AndroGel Records In Chancery
• 5 Takeaways As White House Dishes On Drug Prices
• Immunomedics, VenBio Settle Del. Proxy Fight Claims
• Biomet Denied Early Wins In Metal Hip Replacements MDL
• Hospital Wants Last Meningitis Case Back In Md.
• Insulet Agrees To Pay $19.5M To End Investor Suit
• Consumers Seek Sanctions For Destroyed Abilify Evidence
• Merck Loses Fed. Circ. Bid To Enforce Nasonex Patent
• Health Hires: Ropes, Brown Rudnick, Mallinckrodt, DLA Piper
• Indivior Sues Teva, Others Over Opioid Addiction Generics
• Gov't Steps Into Eye Products FCA Suit After $3M Settlement
• Wis. Tribe Sues State For Right To Grow Hemp
• Former Aveo Chief Medical Officer Ordered To Pay SEC $50K
• D&O Insurance Coverage For Government Investigations
• ITC Receives Infringement Complaint Over Light Engines
• Cherokee AG Wants Federal Opioid Jurisdiction Case Dropped
• Agency Guidance Limits May Shift Health Care Enforcement
• Fed. Circ. Revives Knee Brace Patent Application
• J&J Hit With Stock-Drop Suit Over Claims Of Asbestos In Talc
• Purdue Says Collegium's Nucynta Sales Infringe 3 Patents
• Biologic Fights Drive PTAB Drug Challenges To Record High
• Deals Rumor Mill: BlackRock, Bayer, Atlantia
• MD's Knowledge Of Risks Bars Hernia Patch Defect Claims
• Sens. Unveil Bill Aimed At Curbing Opioid Crisis
• The Art Of The Litigation Funding Deal
• 11th Circ. Revives Defibrillator Failure Claims Against Zoll
• 5 Cos. Price IPOs Totaling $959M Despite Market Turbulence
• Lewis Brisbois Nabs Baker Donelson IP Pro
• Safe Harbor Protects Protagonist From Infringement Suit
• Cooley Guides Canadian Pot Co.'s $48M Funding Round
• Power, Corruption And Lies: How Juries Are Responding
• FDA Approves Gilead's HIV Med; Rival Claims Infringement
• PTAB Upholds Patent For Medac's Arthritis Drug Injector
• Atty Negotiating Teams Set In Opioid MDL
• FDA's Off-Label Delay Not Enough For Big Drugmakers
• 3rd Circ. Denies GSK Rehearing Bid In Flonase Antitrust Suit
• Senators Urge FDA To Reject Philip Morris Tobacco Device
• AbbVie Filed Patent Suits To Delay Competition, Court Told
• 2017 Patent Litigation: A Year In Review
• Hospital To Face Some Claims In Last Meningitis MDL Case
• Smart Contracts Need Smart Corporate Lawyers
• Pa. Medical Pot Bidder Grilled Over Permit Challenge
• Sanofi Urges Fed. Circ. To Deny Amgen's Redo Bid In IP Row
• Drunk Elephant Trumpets False Skin Benefits, Consumer Says
• Bellicum Hit With Stock Drop Suit In Texas Over Drug Risks
• Witness Preparation Also Requires Witness Training
• New Normal Takes Shape After TC Heartland Shakeup
• ITC Patent Rebound Shows Signs It's Here To Stay
• Beyond Gilstrap: 5 Judges To Watch In Patent Litigation
• How Patent Litigation Changed In 2017
• The Firms That Fielded The Most Patent Cases
• Drop In IPRs Tied To Patent Litigation Slowdown
• After Tragedy, Mom Says Pharmacists Must Seek Docs' Rx OK
• Fed. Circ. Says On-Sale Bar May Invalidate Angiomax Patent
• Gag Order Issued Over Opioid MDL Settlement Talks
• Boehringer, Teva Fight Humana's Bid To Block Aggrenox Deal
• Fed. Circ. Backs USPTO's Term Adjustment For Drug Patent
• FDA Warning Wire: Zimmer Biomet Zapped Again
• Stericycle To Pay Workers $2M To End Wage, Break Claims
• Adocia Adds $200M To Arbitration Demand Against Eli Lilly
• 4th Circ. Upholds $18.5M Boston Scientific Mesh Verdict
• How To Fix Your Broken Client Teams
• Valeant Seeks To Move NY Investor Fraud Suit To NJ
• Alabama Sues Purdue Pharma Over Role In Opioid Crisis
• Omnicare Settlement: Outlier Or Beginning Of Broader Trend?
• Preemption In Pharmaceutical Cases: 2017 In Review
• Surgery Center, Estate Contest Punitives In Meningitis MDL
• Ex-Doc Gets 8 Years For Fraud, Illegally Dispensing Opioids
• Bayer Offers Commitments To EU For $63.5B Monsanto Buy
• Cornell University Can't Restart Settled Patent Fight
• Ex-Aveo Exec Fights SEC Penalty, Says He's Learned Lesson
• Fed. Circ. Backs Toss Of AbbVie's Humira License Suit
• Deals Rumor Mill: Pfizer, ADM, Bhushan Steel
• US Teva Worker Can Sue Co.'s Israeli Branch, Judge Says
• Vertex To Pay $4.75M To End TCPA Case Over Hep C Faxes
• Atty Scolded For '#Killinnazis' Exits Pa. Xarelto Cases
• IRS Asks Supreme Court To Skip Appeal In Marijuana Case
• Filter MDL Puts FDA Clearance Evidence Back On The Table
• Amgen's Suit To Shield Cancer Treatment Biosimilar Tossed
• Biomed Co. Appealed Too Late In Trade Secrets Row: 7th Circ.
• 10 Firms To Steer IPOs Exceeding $1.8B To Start February
• $47M Pulled From Biotech Wasn't Returned, Del. Court Told
• 2nd Circ. Affirms Dismissal Of Dr. Scholl's Class Action
• Georgia Man Gets 5 Years For $20M Investment Scheme
• Mylan Says Celgene Claims Still Timely In Antitrust Suit
• Philly DA Accuses Drugmakers Of Deceptive Opioid Marketing
• 9th Circ. Botched Escobar Standard, High Court Hears
• Buchalter Adds 3 IP Pros From Greenberg Traurig
• Deals Rumor Mill: Boeing, Alibaba, Nestle
• Aveo Agrees To $18M Deal To End Cancer Drug Investor Suit
• Ex-Biotech CFO Avoids Prison For Hornswoggling Auditor
• How To Serve Your Blind Client Effectively
• 1 Firm Leads January IPO Activity As 2018 Starts Bullish
• NY AG Sues Insys Over 'Perilous' Opioid Marketing
• Insurers Sue Pfizer To Avoid Covering $400M Settlement
• Inside The Opioid MDL's Big Closed-Door Hearing
• Life Sciences Group Of The Year: Sullivan & Cromwell
• Intercept Drug Gets Black-Box Warning After Dosing Deaths
• 5th Circ. Won't Interfere With Opioid Probe Into Texas Doc
• DuPont Whistleblower Didn't Exhaust Options, 3rd. Circ. Says
• Allergan To Pay Teva $700M To End Working-Capital Dispute
• Evolving Due Process In The Digital Age
• DOJ Has New Policy On FCA Dismissals — Finally